Hybryte™ expanded treatment continues to demonstrate positive outcomes in early-stage cutaneous t-cell lymphoma

Study supported by $2.6 million fda orphan products development grant princeton, n.j. , jan. 14, 2025 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced an interim update on the open-label, investigator-initiated study (iis) evaluating extended hybryte™ (synthetic hypericin) treatment for up to 12 months in patients with early-stage cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking